Denali Therapeutics Inc. (DNLI) /

The cash flow of Denali Therapeutics Inc. over the past 10 years

Chart Denali Therapeutics Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →

In fiscal 2025, the latest fiscal year on file, Denali Therapeutics Inc.'s operating cash flow was -$412.6M and its capital expenditures $9.5M, leaving free cash flow of -$422.1M. Free cash flow was above zero in 2 of the 10 years shown. It ranged from -$422.1M in fiscal 2025 to $413.06M in fiscal 2020. Capital expenditures were highest in fiscal 2019, at $17.92M.

Year by year

Fiscal yearOperating cash flowCapital expendituresFree cash flow*
2025ended Dec 31, 2025-$412.6M$9.5M-$422.1M
2024ended Dec 31, 2024-$347.69M$15.91M-$363.61M
2023ended Dec 31, 2023-$357.99M$12.94M-$370.93M
2022ended Dec 31, 2022-$244.72M$17.83M-$262.55M
2021ended Dec 31, 2021-$211.39M$8.5M-$219.89M
2020ended Dec 31, 2020$416.15M$3.1M$413.06M
2019ended Dec 31, 2019-$151.58M$17.92M-$169.5M
2018ended Dec 31, 2018$50.12M$3.39M$46.72M
2017ended Dec 31, 2017-$76.64M$2.88M-$79.51M
2016ended Dec 31, 2016-$71.91M$6.13M-$78.04M

Fiscal years as Denali Therapeutics Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.

More on Denali Therapeutics Inc.

Companies of a similar size

Not investment advice. This page shows what Denali Therapeutics Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.